Skip to main content

Select Drug Profiles

Original Research
Longitudinal Commercial Claims–Based Cost Analysis of Diabetic Retinopathy Screening Patterns
Kathryn Fitch, RN, MEd, Thomas Weisman, MD,MBA, Tyler Engel, ASA, MAAA, Adam Turpcu, PhD, Helen Blumen, MD, MBA, Yamina Rajput, MS, Purav Dave, MS, MBA
Stakeholder Perspective
The Economics of Screening Patients with Diabetes for Diabetic Retinopathy
by Sharon Glave Frazee, PhD, MPH
Read More
Practice Management
Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus
Janice M.S. Lopez, PharmD, MPH, Brian Macomson, PharmD, Varun Ektare, MPH, Dipen Patel, PhD, Marc Botteman, MSc
Stakeholder Perspective
Evaluating the Benefits and Cost of the Sodium-Glucose Cotransporter 2 Inhibitors
by Quang T. Nguyen, DO, FACE, FTOS
Read More
Practice Management
The Impact of HbA1c Testing on Total Annual Healthcare Expenditures Among Newly Diagnosed Patients with Diabetes
Prajakta Bhounsule, MS, Andrew M. Peterson, PharmD, PhD
Stakeholder Perspective
Saving Money Is Not Always the Objective
by Gary M. Owens, MD
Read More
FDA Approvals
Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure
Loretta Fala
Read More
Perspectives
Ahead of the Curve
David B. Nash, MD, MBA
Read More
Perspectives
Guiding Employer Management of Specialty Drugs
Cheryl Larson, F. Randy Vogenberg, PhD, FASHP
Read More
Practice Management
Trends in Medicare Part D Medication Therapy Management Eligibility Criteria
Junling Wang, PhD, Ya-Chen Tina Shih, PhD, Yolanda Qin, Theo Young, BS, Zachary Thomas, MS, MBA, Christina A. Spivey, PhD, David K. Solomon, BSc, PharmD, Marie Chisholm-Burns, PharmD, MPH, MBA, FCCP, FASHP, J. Warren Salmon, PhD
Stakeholder Perspective
Is It Time to Revisit Medicare Part D?
by J. Warren Salmon, PhD
Read More
Original Research
Value-Based Benefit Design to Improve Medication Adherence for Employees with Anxiety or Depression
Kimberly J. Reid, MS, Kathleen M. Aguilar, MPH, Eric Thompson, MBA, Ross M. Miller, MD, MPH
Stakeholder Perspective
Counting on a Run of Value-Based Benefit Design
by Albert Tzeel, MD, MHSA, CPE, FAAPL
Read More
Practice Management
US Healthcare Annual Spending Estimated to Rise by 5.8% on Average Through 2024
Laura Morgan
Read More
Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens
Lee Schwartzberg, MD, Brooke Harrow, PhD, Lincy S Lal, PharmD, PhD, Janna Radtchenko, MBA, Gary H. Lyman, MD, MPH
Stakeholder Perspective
Impact of Chemotherapy-Induced Nausea and Vomiting Treatment on Patient Outcomes and Resource Utilization
by James T. Kennedy, Jr, RPh, MBA
Read More
Page 127 of 244
Results 1261 - 1270 of 2438